Orphan Drug Prices Under Siege in Austerity-Minded Europe

Treatments for rare diseases are hot properties for drugmakers, who covet the medicines for their exclusive markets, tax breaks and through-the-roof prices. Now that’s changing.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.